HIGHLIGHTS
- who: Houyong Zhu from the United States Sapienza of Rome, Italy United States have published the research work: Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials, in the Journal: (JOURNAL)
- what: In SCVD populations at high ischemic risk, such as CAD with multi-vessel disease or history of MI, symptomatic PAD or limb revascularization or amputation, ticagrelor plus aspirin, clopidogrel plus aspirin, or rivaroxaban plus aspirin reduced MACEs but increased the risk of major bleeding, with ticagrelor plus aspirin having . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.